Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat

Siddika E Karakas, John Elovson, Sheila Khilnani, Rogelio U. Almario, K. L. Catherine Jen

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Recent studies demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase lower plasma triglyceride primarily by decreasing hepatic secretion of very low density lipoproteins (VLDL). A possible mechanism is that inhibition of cholesterol synthesis interferes with the assembly of VLDL particles. Since one molecule of apolipoprotein (apo) B is required for the proper assembly and secretion of each VLDL and secretion of apo B may be regulated by various lipid components of the lipoproteins, question arises whether HMG-CoA reductase inhibitors also decrease the secretion of apo B. To address this issue, we investigated the effect of lovastatin on the secretion rate of VLDL-apo B and on the composition of VLDL in the Zucker obese rat; a model for genetic hypertriglyceridemia. Lovastatin treatment (4 mg/kg day × 13 days), as compared with placebo, decreased the concentrations of fasting plasma triglyceride (1740 ± 170 vs. 3130 ± 790 μg/ml) and VLDL-triglyceride (1379 ± 59 vs. 3082 ± 715 μg/ml). There was a small but non-significant decrease in VLDL-apo B (19 ± 2 μg/ml vs. 26 ± 7 μg/ml). Thus, lovastatin significantly decreased the ratio of triglyceride to apo B in VLDL (76 in lovastatin vs. 124 in placebo group). Secretion rates of VLDL-lipids and VLDL-apo B were measured after intravenous injection of Triton WR-1339. Lovastatin, as compared with placebo, decreased the secretion rates of plasma triglyceride (78 vs. 123 μg/ml per min) and VLDL-triglyceride (102 vs. 167 μg/ml per min) significantly, but not of VLDL-phospholipid (11 vs. 14 μg/ml per min), VLDL-free cholesterol (5.3 vs. 6.6 μg/ml per min) or VLDL-apo B (1.1 vs. 1.0 μg/ml per min). Consequently, newly-secreted VLDL particles had a significantly smaller ratio of triglyceride to apo B (91 vs. 184) and smaller estimated particle sizes (46 + 2.4 nm vs. 58 + 2.6 nm in diameter). In summary, the present study demonstrated that, in the hypertriglyceridemic state, lovastatin interfered with the secretion of VLDL-triglyceride but not of VLDL-apo B, resulting in the production of smaller, triglyceride-depleted VLDL particles.

Original languageEnglish (US)
Pages (from-to)147-152
Number of pages6
JournalAtherosclerosis
Volume104
Issue number1-2
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Zucker Rats
Lovastatin
VLDL Lipoproteins
Apolipoproteins B
Lipids
Triglycerides
Placebos
Oxidoreductases
VLDL Cholesterol
Hypertriglyceridemia
Genetic Models
Particle Size
Intravenous Injections
Lipoproteins

Keywords

  • HMG-CoA reductase inhibitors
  • VLDL-apo B
  • VLDL-composition
  • Zucker fa/fa rat

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat. / Karakas, Siddika E; Elovson, John; Khilnani, Sheila; Almario, Rogelio U.; Catherine Jen, K. L.

In: Atherosclerosis, Vol. 104, No. 1-2, 1993, p. 147-152.

Research output: Contribution to journalArticle

Karakas, Siddika E ; Elovson, John ; Khilnani, Sheila ; Almario, Rogelio U. ; Catherine Jen, K. L. / Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat. In: Atherosclerosis. 1993 ; Vol. 104, No. 1-2. pp. 147-152.
@article{0542db91a71d432da923055c9f454cb4,
title = "Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat",
abstract = "Recent studies demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase lower plasma triglyceride primarily by decreasing hepatic secretion of very low density lipoproteins (VLDL). A possible mechanism is that inhibition of cholesterol synthesis interferes with the assembly of VLDL particles. Since one molecule of apolipoprotein (apo) B is required for the proper assembly and secretion of each VLDL and secretion of apo B may be regulated by various lipid components of the lipoproteins, question arises whether HMG-CoA reductase inhibitors also decrease the secretion of apo B. To address this issue, we investigated the effect of lovastatin on the secretion rate of VLDL-apo B and on the composition of VLDL in the Zucker obese rat; a model for genetic hypertriglyceridemia. Lovastatin treatment (4 mg/kg day × 13 days), as compared with placebo, decreased the concentrations of fasting plasma triglyceride (1740 ± 170 vs. 3130 ± 790 μg/ml) and VLDL-triglyceride (1379 ± 59 vs. 3082 ± 715 μg/ml). There was a small but non-significant decrease in VLDL-apo B (19 ± 2 μg/ml vs. 26 ± 7 μg/ml). Thus, lovastatin significantly decreased the ratio of triglyceride to apo B in VLDL (76 in lovastatin vs. 124 in placebo group). Secretion rates of VLDL-lipids and VLDL-apo B were measured after intravenous injection of Triton WR-1339. Lovastatin, as compared with placebo, decreased the secretion rates of plasma triglyceride (78 vs. 123 μg/ml per min) and VLDL-triglyceride (102 vs. 167 μg/ml per min) significantly, but not of VLDL-phospholipid (11 vs. 14 μg/ml per min), VLDL-free cholesterol (5.3 vs. 6.6 μg/ml per min) or VLDL-apo B (1.1 vs. 1.0 μg/ml per min). Consequently, newly-secreted VLDL particles had a significantly smaller ratio of triglyceride to apo B (91 vs. 184) and smaller estimated particle sizes (46 + 2.4 nm vs. 58 + 2.6 nm in diameter). In summary, the present study demonstrated that, in the hypertriglyceridemic state, lovastatin interfered with the secretion of VLDL-triglyceride but not of VLDL-apo B, resulting in the production of smaller, triglyceride-depleted VLDL particles.",
keywords = "HMG-CoA reductase inhibitors, VLDL-apo B, VLDL-composition, Zucker fa/fa rat",
author = "Karakas, {Siddika E} and John Elovson and Sheila Khilnani and Almario, {Rogelio U.} and {Catherine Jen}, {K. L.}",
year = "1993",
doi = "10.1016/0021-9150(93)90185-W",
language = "English (US)",
volume = "104",
pages = "147--152",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat

AU - Karakas, Siddika E

AU - Elovson, John

AU - Khilnani, Sheila

AU - Almario, Rogelio U.

AU - Catherine Jen, K. L.

PY - 1993

Y1 - 1993

N2 - Recent studies demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase lower plasma triglyceride primarily by decreasing hepatic secretion of very low density lipoproteins (VLDL). A possible mechanism is that inhibition of cholesterol synthesis interferes with the assembly of VLDL particles. Since one molecule of apolipoprotein (apo) B is required for the proper assembly and secretion of each VLDL and secretion of apo B may be regulated by various lipid components of the lipoproteins, question arises whether HMG-CoA reductase inhibitors also decrease the secretion of apo B. To address this issue, we investigated the effect of lovastatin on the secretion rate of VLDL-apo B and on the composition of VLDL in the Zucker obese rat; a model for genetic hypertriglyceridemia. Lovastatin treatment (4 mg/kg day × 13 days), as compared with placebo, decreased the concentrations of fasting plasma triglyceride (1740 ± 170 vs. 3130 ± 790 μg/ml) and VLDL-triglyceride (1379 ± 59 vs. 3082 ± 715 μg/ml). There was a small but non-significant decrease in VLDL-apo B (19 ± 2 μg/ml vs. 26 ± 7 μg/ml). Thus, lovastatin significantly decreased the ratio of triglyceride to apo B in VLDL (76 in lovastatin vs. 124 in placebo group). Secretion rates of VLDL-lipids and VLDL-apo B were measured after intravenous injection of Triton WR-1339. Lovastatin, as compared with placebo, decreased the secretion rates of plasma triglyceride (78 vs. 123 μg/ml per min) and VLDL-triglyceride (102 vs. 167 μg/ml per min) significantly, but not of VLDL-phospholipid (11 vs. 14 μg/ml per min), VLDL-free cholesterol (5.3 vs. 6.6 μg/ml per min) or VLDL-apo B (1.1 vs. 1.0 μg/ml per min). Consequently, newly-secreted VLDL particles had a significantly smaller ratio of triglyceride to apo B (91 vs. 184) and smaller estimated particle sizes (46 + 2.4 nm vs. 58 + 2.6 nm in diameter). In summary, the present study demonstrated that, in the hypertriglyceridemic state, lovastatin interfered with the secretion of VLDL-triglyceride but not of VLDL-apo B, resulting in the production of smaller, triglyceride-depleted VLDL particles.

AB - Recent studies demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase lower plasma triglyceride primarily by decreasing hepatic secretion of very low density lipoproteins (VLDL). A possible mechanism is that inhibition of cholesterol synthesis interferes with the assembly of VLDL particles. Since one molecule of apolipoprotein (apo) B is required for the proper assembly and secretion of each VLDL and secretion of apo B may be regulated by various lipid components of the lipoproteins, question arises whether HMG-CoA reductase inhibitors also decrease the secretion of apo B. To address this issue, we investigated the effect of lovastatin on the secretion rate of VLDL-apo B and on the composition of VLDL in the Zucker obese rat; a model for genetic hypertriglyceridemia. Lovastatin treatment (4 mg/kg day × 13 days), as compared with placebo, decreased the concentrations of fasting plasma triglyceride (1740 ± 170 vs. 3130 ± 790 μg/ml) and VLDL-triglyceride (1379 ± 59 vs. 3082 ± 715 μg/ml). There was a small but non-significant decrease in VLDL-apo B (19 ± 2 μg/ml vs. 26 ± 7 μg/ml). Thus, lovastatin significantly decreased the ratio of triglyceride to apo B in VLDL (76 in lovastatin vs. 124 in placebo group). Secretion rates of VLDL-lipids and VLDL-apo B were measured after intravenous injection of Triton WR-1339. Lovastatin, as compared with placebo, decreased the secretion rates of plasma triglyceride (78 vs. 123 μg/ml per min) and VLDL-triglyceride (102 vs. 167 μg/ml per min) significantly, but not of VLDL-phospholipid (11 vs. 14 μg/ml per min), VLDL-free cholesterol (5.3 vs. 6.6 μg/ml per min) or VLDL-apo B (1.1 vs. 1.0 μg/ml per min). Consequently, newly-secreted VLDL particles had a significantly smaller ratio of triglyceride to apo B (91 vs. 184) and smaller estimated particle sizes (46 + 2.4 nm vs. 58 + 2.6 nm in diameter). In summary, the present study demonstrated that, in the hypertriglyceridemic state, lovastatin interfered with the secretion of VLDL-triglyceride but not of VLDL-apo B, resulting in the production of smaller, triglyceride-depleted VLDL particles.

KW - HMG-CoA reductase inhibitors

KW - VLDL-apo B

KW - VLDL-composition

KW - Zucker fa/fa rat

UR - http://www.scopus.com/inward/record.url?scp=0027732505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027732505&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(93)90185-W

DO - 10.1016/0021-9150(93)90185-W

M3 - Article

C2 - 8141838

AN - SCOPUS:0027732505

VL - 104

SP - 147

EP - 152

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1-2

ER -